Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $51 | $49 | $33 | $42 |
| % Growth | 5.8% | 48.3% | -21.8% | – |
| Cost of Goods Sold | $5 | $6 | $4 | $4 |
| Gross Profit | $46 | $43 | $29 | $38 |
| % Margin | 89.3% | 88.6% | 88.8% | 90.9% |
| R&D Expenses | $46 | $42 | $37 | $41 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $52 | $46 | $39 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $98 | $88 | $76 | $79 |
| Operating Income | -$53 | -$45 | -$47 | -$41 |
| % Margin | -102.6% | -93.4% | -143.7% | -98.6% |
| Other Income/Exp. Net | -$0 | -$1 | -$2 | -$2 |
| Pre-Tax Income | -$53 | -$46 | -$49 | -$43 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$53 | -$47 | -$49 | -$43 |
| % Margin | -103.1% | -96.1% | -151.4% | -103.5% |
| EPS | -0.82 | -0.75 | -0.81 | -0.72 |
| % Growth | -9.3% | 7.4% | -12.5% | – |
| EPS Diluted | -0.82 | -0.75 | -0.81 | -0.72 |
| Weighted Avg Shares Out | 64 | 64 | 63 | 62 |
| Weighted Avg Shares Out Dil | 64 | 64 | 63 | 62 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $3 | $4 | $4 |
| Interest Expense | $5 | $6 | $5 | $5 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$48 | -$40 | -$44 | -$38 |
| % Margin | -93.1% | -82.7% | -133.4% | -89.8% |